Trials
Search / Trial NCT06418451

A Randomized Controlled Trial of Modified Ischial Spinous Fascia Fixation and Sacrospinous Ligament Fixation in the Treatment of Pelvic Organ Prolapse

Launched by LAN ZHU · May 13, 2024

Trial Information

Current as of February 12, 2025

Not yet recruiting

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Patients with symptomatic mid-pelvic organ prolapse (POP-Q stage ≥ II) who may concurrently have anterior and/or posterior pelvic organ prolapse.
  • Patients willing to undergo long-term follow-up for at least one year.
  • Patients willing to sign an informed consent form and participate in this study.
  • Exclusion Criteria:
  • Patients who have undergone previous POP or urinary incontinence surgery with the use of implant materials.
  • Patients who require simultaneous anti-urinary incontinence surgery for the current procedure.
  • Contraindications for general anesthesia and surgical intervention, such as severe medical comorbidities that render the patient unable to tolerate surgery.
  • Patients who wish to preserve the uterus.
  • Patients in the active phase of genital, urinary, or systemic infections.
  • Patients who, for other reasons (such as having genital malignancies), choose not to undergo SSLF/modified ISFF surgical intervention at the moment.
  • Patients who are unable or unwilling to attend follow-up visits (excluding those who may be willing to participate in telephone follow-up).

Trial Officials

Lan Zhu, MD

Principal Investigator

Peking Union Medical College Hospital

About Lan Zhu

Lan Zhu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on integrity and scientific rigor, Lan Zhu collaborates with leading healthcare professionals and institutions to design and execute clinical trials that address unmet medical needs. The organization prioritizes patient safety and ethical standards, ensuring that all trials adhere to regulatory guidelines while fostering a culture of transparency and collaboration. By leveraging cutting-edge methodologies and data-driven insights, Lan Zhu aims to contribute to the development of effective therapies that enhance patient outcomes and improve public health.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0